In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy

Regardless of the recent advances in cytotoxic therapies, 30% of children diagnosed with medulloblastoma. succumb to the disease. Therefore, novel therapeutic approaches are warranted. Here we demonstrate that Pazopanib a clinically approved multi-kinase angiogenesis inhibitor (MKI) inhibits prolife...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Craveiro, Rogerio B., Ehrhardt, Michael, Holst, Martin I., Pietsch, Thorsten, Dilloo, Dagmar
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2014
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4196191/
https://ncbi.nlm.nih.gov/pubmed/25216529
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky